News

Company News & Events

ORYZON committed to rare diseases with its research in acute myeloid leukemia

28 February 2020

World Rare Disease Day

 

MADRID, SPAIN and CAMBRIDGE MA.

  • Ongoing Phase II ALICE clinical trial with iadademstat shows efficacy in elderly patients with acute myeloid leukemia
  • Obtained in 2013 the designation of iadademstat as an orphan drug for AML by the European Medicines Agency
  • Also exploring genetic variants of autism and schizophrenia

 

Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a public clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, continues to contribute to the fight against rare diseases, whose world day is celebrated on February 29th, through its research on acute myeloid leukemia (AML).

 

Click here to see the full Press Release

 

Posted In: 
News
Investors

Share this story